Use of a vaccine against peste des petits ruminants - capripox

Abstract

This invention belongs to the field of goat vaccine technology and is an application of a vaccine for the prevention of small ruminant plague (PPR) and sheep pox. This PPR-sheep pox vaccine is an improvement on the injection method of a bivalent live PPR-sheep pox vaccine, suitable for doubling the intramuscular injection in goats. Each injection of 1 ml of the bivalent live PPR-sheep pox vaccine results in a population antibody titer of 70% for both PPR and sheep pox after 30 days, and sheep pox antibody titer can still be detected after 180 days. This PPR-sheep pox vaccine demonstrates good safety and PPR immunity protection in Alashan white cashmere goats. Furthermore, the vaccine is suitable for intramuscular injection, which meets the needs of sheep pox immunization and control, and is suitable for practical grassroots disease prevention operations. It provides important technical support for the scientific prevention and control of diseases in regional white cashmere goats. Promoting the use of this PPR-sheep pox vaccine can prevent both PPR and sheep pox.

Description

Technical Field

[0001] This invention belongs to the field of goat vaccine technology, specifically relating to the application of a vaccine for the prevention of small ruminant disease - sheep pox. Background Technology

[0002] Alashan White Cashmere Goat is one of my country's goat breeds, mainly concentrated in the Alashan region of Inner Mongolia. Alashan White Cashmere Goats are generally free-range and highly adaptable to their environment. However, they are susceptible to peste des petits ruminants (PPR) and goat pox. PPR is a major animal disease requiring immunization, while goat pox is a local endemic infectious disease in Alashan. The PPR-goat pox bivalent live vaccine is a new type of vaccine that can prevent both PPR and goat pox. The required injection method for the PPR-goat pox bivalent live vaccine is intradermal. However, in practice, intradermal injection is difficult for vaccination personnel to master, and it is commonly injected subcutaneously or intramuscularly, resulting in less than ideal vaccine efficacy. Summary of the Invention

[0003] This invention aims to provide an application of a vaccine for the prevention of small ruminant disease-sheep pox, and to solve the problem of difficulty in injecting the Alashan white cashmere goat small ruminant disease-sheep pox bivalent live vaccine.

[0004] Several manufacturers currently offer a bivalent live vaccine for peste des petits ruminants (PPR) and sheep pox. Existing PPR-sheep pox bivalent live vaccine is a sponge-like, loose, freeze-dried vaccine with fixed specifications, typically 50 or 100 doses per vial. One vial of 50 doses is sufficient for immunizing 50 sheep, and one vial of 100 doses is sufficient for immunizing 100 sheep. When using it, it is diluted with sterile saline to a concentration of one dose per 0.5 ml, and 0.5 ml is injected intradermally into each sheep. In practice, intradermal injection is difficult for disease control personnel to master, often resulting in subcutaneous or intramuscular injection, leading to less than ideal vaccine efficacy. Based on the existing vaccine usage, the inventors provide a new method of vaccine application to facilitate better control by disease control personnel and improve disease prevention effectiveness.

[0005] To achieve the above objectives, the present invention adopts the following technical solution: An application of a vaccine for the prevention of small ruminant plague-sheep pox is provided. The vaccine comprises 1 ml of a bivalent live small ruminant plague-sheep pox vaccine for intramuscular injection. The 1 ml of the bivalent live small ruminant plague-sheep pox vaccine for intramuscular injection is taken from a vaccine diluent prepared by diluting the bivalent live small ruminant plague-sheep pox vaccine labeled with an injection dose of 0.5 ml / head and n doses / vial into n equal portions. This vaccine for the prevention of small ruminant plague-sheep pox is used for the combined immunization of sheep against small ruminant plague and sheep pox.

[0006] The present invention also provides the application of the aforementioned preventive vaccine against small ruminant disease-sheep pox in the combined immunization of sheep against small ruminant disease and sheep pox.

[0007] Preferably, the sheep is an Alashan white cashmere goat.

[0008] Compared with existing technologies, the beneficial effects of this invention are as follows: This invention's PPR-sheeppox vaccine is an improvement upon the application of a PPR-sheeppox bivalent live vaccine. This PPR-sheeppox vaccine is suitable for doubling intramuscular injection into goats. Each injection of 1 ml of the PPR-sheeppox bivalent live vaccine results in a 70% herd antibody titer for both PPR and goatpox after 30 days. Sheeppox antibody titers can still be detected at 180 days. This PPR-sheeppox vaccine demonstrates good safety and PPR immunity protection in Alashan white cashmere goats. As it is suitable for intramuscular injection, this method meets the needs of sheep pox immunization and is suitable for practical grassroots disease prevention operations. It provides important technical support for the scientific prevention and control of diseases in regional white cashmere goats. Promoting the use of this PPR-sheeppox vaccine can prevent both PPR and sheep pox. Attached Figure Description

[0009] The accompanying drawings are provided to further illustrate the invention and form part of the specification. They are used in conjunction with embodiments of the invention to explain the invention and do not constitute a limitation thereof. In the drawings: Figure 1 This is a grouping chart of immunization experiments conducted using different injection methods in one embodiment of the application of the small ruminant disease-sheep pox vaccine of the present invention.

[0010] Figure 2 The image shows the ELISA test results in one embodiment of the application of the small ruminant disease-sheep pox vaccine of the present invention.

[0011] Figure 3 The results of sheep pox antibody detection are shown in one embodiment of the application of the sheep pox vaccine for the prevention of peste des petits ruminants according to the present invention. Detailed Implementation

[0012] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0013] In one embodiment, an application of a vaccine for the prevention of small ruminant pox-sheep pox is provided, the application of which includes 1 ml of small ruminant pox-sheep pox bivalent live vaccine for intramuscular injection; the 1 ml of small ruminant pox-sheep pox bivalent live vaccine for intramuscular injection is taken from a vaccine diluent obtained by diluting the small ruminant pox-sheep pox bivalent live vaccine labeled with an injection volume of 0.5 ml / head into n equal parts.

[0014] For example, the 50-dose / bottle bivalent live vaccine for small ruminant goats can be used to prepare the vaccine. Prepare 25ml of the 50-dose / bottle bivalent live vaccine for small ruminant goats, and take 1ml to obtain the small ruminant plague-goat pox vaccine in this embodiment.

[0015] This vaccine against small ruminant plague and goat pox can be used for combined immunization of goats against small ruminant plague and goat pox, specifically Alashan white cashmere goats.

[0016] To verify the effectiveness of the present invention in preventing small ruminant disease-sheep pox vaccine, immunization experiments were conducted in groups using several different vaccination methods, as detailed below: Grouping: In Burigestai Gacha Village, Jilantai Town, the main production area of ​​white cashmere goats in Alxa Left Banner, a group of white cashmere goats were selected as experimental subjects. Based on the injection method, they were divided into intradermal injection group, subcutaneous injection group, and intramuscular injection group. Immunization was performed by intradermal injection of 0.5 ml, and subcutaneous and intramuscular injection of 1 ml (see details). Figure 1 Serum samples were collected at five time points: before immunization, 30 days, 60 days, 90 days, and 180 days after immunization. The antibody levels of small ruminants and sheep pox were detected by ELISA and compared and analyzed.

[0017] Test method: Small Ruminant Disease (PRU) Competition ELISA: ① Add 50 μl of the serum to be tested to each well of the coated plate. Add 50 μl of serum to each well for positive and negative controls (2 wells each). Add 100 μl of 1-fold PBST to each well of the blank control (2 wells). Add 50 μl of 1-fold PBST to each well of the monoclonal antibody control (4 wells). ② Add 50 μl of monoclonal antibody working solution to each well (except for the blank control). Seal the plate and incubate at 37°C for 60 min. ③ Wash the plate 4-5 times. ④ Add 50 μl of rabbit anti-mouse enzyme-labeled working solution to each well. Seal the plate and incubate at 37°C for 60 min. ⑤ Wash the plate 4-5 times. Mix TMB substrates A and B in equal proportions and add 50 μl to each well. Incubate at 37°C in the dark for 15 min. ⑥ Add 50 μl of stop solution to each well and read the value using a microplate reader. Result interpretation: Serum PI ≥ 45%, antibody positive; PI < 40%, antibody negative; 40% < PI < 45%, questionable.

[0018] Universal double-antigen sandwich ELISA for sheep pox virus: ① Add 50 μl of the test serum to each well of the coated plate, and add 50 μl of serum to each well for both positive and negative controls. Add 50 μl of serum diluent to each well, seal the plate, and incubate at 37°C for 45 min. ② Wash the plate three times, add 100 μl of HRP enzyme conjugate, seal the plate, and incubate at 37°C for 30 min. ③ Wash the plate three times, add 100 μl of chromogenic solution to each well, and incubate at 37°C in the dark for 15 min. ④ Add 50 μl of stop solution to each well and read the value using a microplate reader. Result interpretation: S / CO value < 1.4 indicates antibody negative; S / CO value ≥ 1.4 indicates antibody positive.

[0019] Test results and analysis: Results of early ruminant disease immunity antibody testing (see details) Figure 2 According to the table, the antibody level reached 100% on day 30 after immunization, and remained above the national standard of 70% until day 180, indicating that the bivalent vaccine has a very ideal immunization effect against peste des petits ruminants.

[0020] Based on the results of sheep pox antibody testing (see...) Figure 2 and Figure 3 Thirty days after immunization, antibody levels in all three groups reached their highest levels. The intramuscular and intradermal injection groups exceeded the national standard by 70%, indicating successful immunization, with the intramuscular injection group showing a slightly higher success rate than the intradermal injection group. Antibody levels decreased at 60, 90, and 180 days after immunization, all falling below 70%, with the subcutaneous injection group showing the most significant rate of decline. Within 90 days of immunization, there was no significant difference in antibody levels between the intramuscular and intradermal injection groups (p > 0.05). These results indicate that the injection method of this vaccine significantly affects the immunization effect against sheep pox. Subcutaneous injection is not suitable for this bivalent vaccine, while double-dose intramuscular injection achieves the same immunization effect as intradermal injection.

[0021] in conclusion: (1) 0.5 ml of small ruminant-sheep pox bivalent live vaccine was injected intradermally, and 1 ml of small ruminant-sheep pox bivalent live vaccine was injected intramuscularly and subcutaneously for 30 days. The antibody titer of small ruminant in each group reached 100% and remained so until 180 days.

[0022] (2) After intradermal injection of 0.5 ml of PPR-sheeppox bivalent live vaccine and intramuscular and subcutaneous injection of 1 ml of PPR-sheeppox bivalent live vaccine for 30 days, the qualified rate of herd antibody titer for goatpox in the intradermal and intramuscular groups reached 70%, while that in the subcutaneous group did not. However, at 180 days, antibody titers could be detected in all groups, with the intramuscular group consistently showing higher titers than the subcutaneous group.

[0023] (3) Subcutaneous injection is not suitable for this small ruminant-sheep pox bivalent live vaccine, while double the dose of intramuscular injection can achieve the same immunization effect as intradermal injection.

[0024] In the above embodiments, a positive result means that a positive disease test indicates the presence of a virus in the sample, which may be in a patient in the incubation period, an infected person, or a patient in the recovery period; potency testing is the determination of the efficacy of a bioactive substance (vaccine) through quantitative or semi-quantitative methods.

[0025] Based on the above embodiments, it can be seen that the present invention's vaccine for preventing small ruminant peste des petits ruminants (PPR) and sheep pox is an improvement on the injection method of the PPR-sheep pox bivalent live vaccine. The present invention's PPR-sheep pox vaccine is suitable for doubling the intramuscular injection in goats. Each injection of 1 ml of the PPR-sheep pox bivalent live vaccine into goats results in a population antibody titer of 70% for both PPR and goat pox after 30 days. Sheep pox antibody titer can still be detected at 180 days.

[0026] The PPR-sheeppox vaccine of this invention has good safety and PPR-immunization effect on Alashan white cashmere goats. The PPR-sheeppox vaccine of this invention is suitable for intramuscular injection, which can meet the needs of sheep pox immunization and control, and is suitable for the actual operation of grassroots epidemic prevention. It provides important technical support for the scientific prevention and control of diseases in regional white cashmere goats. The promotion and use of the PPR-sheeppox vaccine of this invention can prevent both PPR and sheep pox.

[0027] It should be noted that, in this document, terms such as “comprising,” “including,” or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article, or apparatus.

[0028] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. An application of a vaccine for the prevention of small ruminant plague-sheep pox, characterized in that: The vaccine includes 1 ml of small ruminant-sheep pox bivalent live vaccine for intramuscular injection; the 1 ml of small ruminant-sheep pox bivalent live vaccine for intramuscular injection is taken from the vaccine diluent after being diluted n times with a labeled injection dose of 0.5 ml / head and n doses / vial; this small ruminant-sheep pox prevention vaccine is used for combined immunization of sheep against small ruminant-sheep pox.

2. The application according to claim 1, characterized in that: The sheep in question is an Alashan white cashmere goat.

Images